Horizon Pharma plc (HZNP): Price Target and June Short Interest Disclosure

Horizon Pharma plc (HZNP) : The highest level Horizon Pharma plc (HZNP) is projected to reach is $45 for the short term and the lowest estimate is at $24. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $32.29 and the possibility the share price can swing is $8.46.

Horizon Pharma plc (HZNP) reported a rise of 30.5% or 4,818,076 shares in its short interest. The short figure came in at 14.5% of the total floats. The average daily volume of 5,425,322 shares suggests that the days to cover 20,625,968 short positions, as on June 30,2016, will be 4. On June 15,2016, the short interest was 15,807,892 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, BMO Capital initiates coverage on Horizon Pharma plc (NASDAQ:HZNP). BMO Capital has a Outperform rating on the shares. The rating by the firm was issued on June 29, 2016.


Horizon Pharma plc (NASDAQ:HZNP): stock turned positive on Thursday. Though the stock opened at $18.7, the bulls momentum made the stock top out at $18.74 level for the day. The stock recorded a low of $18.05 and closed the trading day at $18.69, in the green by 1.85%. The total traded volume for the day was 2,740,013. The stock had closed at $18.35 in the previous days trading.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.